The overall surgical success rate was a high 98.3 percent, which is consistent with international pivotal clinical trials and real-world studies, said Leo Tam, senior director of the business unit of transcatheter aortic valve replacement (TAVR) at Edwards Lifesciences China.

Edwards Lifesciences China经导管主动脉瓣置换术（TAVR）业务部门高级主管Leo Tam表示，总体手术成功率高达98.3%，这与国际关键临床试验和现实世界研究一致。

The diagnosis rate of aortic stenosis is still low in China compared with its population size.

与中国的人口规模相比，主动脉狭窄的诊断率仍然很低。

In 2020, the company's transcatheter aortic valve system — Sapien 3 — was approved in China as the first such system imported by the country to help patients with aortic stenosis improve their prognosis and quality of life.

2020年，该公司的经导管主动脉瓣系统Sapien 3在中国获批，成为中国进口的第一个此类系统，帮助主动脉狭窄患者改善预后和生活质量。

However, data from global consultancy Frost & Sullivan showed that the penetration rate of transcatheter aortic valve replacement in China is only 0.3 percent.

然而，全球咨询公司Frost&Sullivan的数据显示，经导管主动脉瓣置换术在中国的渗透率仅为0.3%。

Edwards Lifesciences, a US medical company that manufactures heart valves and hemodynamic monitoring devices, recently announced that its INSPIRIS RESILIA aortic valve has been officially launched in China.

During the third CIIE, the company showcased its transcatheter aortic valve system Sapien 3 along with a series of innovative products for structural heart diseases, intensive care and surgical monitoring.

The launch of the INSPIRIS RESILIA aortic valves is just the first of many according to its "five-year plan".

Venus Medtech is dedicated to providing cardiovascular products for structural heart disease and its first generation of trans-catheter aortic valve replacement or TAVR product, Venus A, was the first such product in the country approved by the China Food and Drug Administration in April 2017.

One recent example was the recent publication of the first 200 commercial case results of the company's transcatheter aortic valve system Sapien 3 performed by Chinese doctors in real-world settings, which demonstrated exciting results, said Mussallem.

"We look forward to continuing our work with hospitals and clinicians around China to address the unmet needs in the treatment of aortic, mitral and tricuspid valve disease, and to generate early data and evidence that'll be relevant globally," he said.

In terms of R&D, the company has been promoting innovations in its core products, including biodegradable stents, transcatheter aortic valve replacement, and cryoballoon ablation to proactively embrace change without waiting for change to be introduced by public healthcare policies, Zang said.